Indeed, our results demonstrated for the first time that the FINDRISC was significantly associated with impairment in insulin secretion and insulin sensitivity, and adverse changes in insulin resistance related traits (increases in BMI, waist, fat percentage, obesity, overweight, TGs, blood pressure, and incident drug-treated hypertension). Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.